Wellstat Immunotherapeutics, LLC

Wellstat Biologics Corporation

Bristol-myers Squibb Pharma Company

Defined Diagnostics, LLC

Pdl Biopharma, Inc.

Jeffrey Allan Miller

Michael Kaleko

Tianci Luo

ChangHung Chen

Beibei Li

Ruigong Wang

William S Groene

Stephen N Mueller

Micky Daniel Tortorella

Robert A Copeland

Ruiqin Liu

Michael A Pratta

Elizabeth C Arner

Eddie Phillip Jeffries

Gary L Davis

Reid W Von Borstel

Paul Hu

Xiaofen Huang

Tzer-Fen Chen

Jouhn-Wern Jang

Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

Antibodies and methods for the detection of cell death

The disclosure relates generally to methods of detecting and quantifying methotrexate (MTX) in a sample. The methods disclosed herein decrease cross-reactivity and improve sensitivity of the detection.

Compounds and methods for the detection of methotrexate

The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.

Complement factor B analogs and their uses

Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK1 8 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.

Oncolytic virus therapy

Envelope viruses (e.g. Newcastle disease virus (NDV)) are formulated for storage at moderately cold temperatures (e.g. &#x2212;20&#xb0; C.). The formulation is an aqueous solution containing the enveloped virus at a concentration of from 10PFU/mL to 10PFU/mL; and a non-reducing saccharide (e.g. sucrose). When the non-reducing saccharide is a disaccharide it is present in the solution at a concentration of from 5% (w/v) to 50% (w/v), and when it is a monosaccharide it is present in the solution at a concentration of from 2.5% (w/v) to 25% (w/v). The solution has an osmotic pressure of about 250 mOs or higher, and has a pH of from 5 to 10.

Stable and filterable enveloped virus formulations

This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.

Assays and peptide substrate for determining aggrecan degrading metallo protease activity

Growing community of inventors

Lincoln University, PA, United States of America

Jeffrey Allan Miller